Capmatinib (BioDeep_00000176980)

   

human metabolite blood metabolite


代谢物信息卡片


2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide

化学式: C23H17FN6O (412.14478039999995)
中文名称: 苯扎米特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
InChI: InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

同义名列表

6 个代谢物同义名

2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide; 2-fluoro-N-Methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; Capmatinib (INCB28060); INC-280NVP-inc280; Capmatinib



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yiming Qi, Jing Li, Sisi Lin, Shuangshuang Wu, Kequn Chai, Xin Jiang, Jiancheng Qian, Cheng Jiang. A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib. Scientific reports. 2024 05; 14(1):11388. doi: 10.1038/s41598-024-62356-w. [PMID: 38762672]
  • Liang-Wei Tseng, John Wen-Cheng Chang, Chiao-En Wu. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report. International journal of molecular sciences. 2022 Oct; 23(19):. doi: 10.3390/ijms231911809. [PMID: 36233109]
  • Xinhui Chen, Xiaoming Cui, Nathalie Pognan, Michelle Quinlan, Shruti Kapoor, Gholamreza Rahmanzadeh, Monica Giovannini, Thomas C Marbury. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study. British journal of clinical pharmacology. 2022 01; 88(1):91-102. doi: 10.1111/bcp.14929. [PMID: 34046915]
  • Arjunmohan Mohan, Sandra M Herrmann. Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2022 01; 79(1):120-124. doi: 10.1053/j.ajkd.2021.04.009. [PMID: 34118303]
  • Michael G Sugiyama, Haotian Cui, Dar'ya S Redka, Mehran Karimzadeh, Edurne Rujas, Hassaan Maan, Sikander Hayat, Kyle Cheung, Rahul Misra, Joseph B McPhee, Russell D Viirre, Andrew Haller, Roberto J Botelho, Raffi Karshafian, Sarah A Sabatinos, Gregory D Fairn, Seyed Ali Madani Tonekaboni, Andreas Windemuth, Jean-Philippe Julien, Vijay Shahani, Stephen S MacKinnon, Bo Wang, Costin N Antonescu. Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease. Scientific reports. 2021 12; 11(1):23315. doi: 10.1038/s41598-021-02432-7. [PMID: 34857794]
  • Sung Ho Ahn, Hyun Jung Lee, Do Hyeon Pyun, Tae Jin Kim, A M Abd El-Aty, Jin-Ho Song, Yong Kyoo Shin, Ji Hoon Jeong, Eon Sub Park, Tae Woo Jung. Capmatinib attenuates lipogenesis in 3T3-L1 adipocytes through an adenosine monophosphate-activated protein kinase-dependent pathway. Biochemical and biophysical research communications. 2021 05; 553(?):30-36. doi: 10.1016/j.bbrc.2021.03.064. [PMID: 33756343]
  • Ibiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, Jochen K Lennerz, Zofia Piotrowska, Jessica J Lin, Inga T Lennes, Lecia V Sequist, Alice T Shaw, Kelly Goodwin, Sara E Stevens, Andrew Do, Subba R Digumarthy, Kristin Price, Alona Muzikansky, Aaron N Hata, Rebecca S Heist. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021 05; 16(5):850-859. doi: 10.1016/j.jtho.2021.01.1605. [PMID: 33545388]
  • Ulrike Glaenzel, Yi Jin, Regine Hansen, Kirsten Schroer, Gholamreza Rahmanzadeh, Ulrike Pfaar, Jan Jaap van Lier, Hubert Borell, Axel Meissner, Gian Camenisch, Sylvia Zhao. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite. Drug metabolism and disposition: the biological fate of chemicals. 2020 10; 48(10):873-885. doi: 10.1124/dmd.119.090324. [PMID: 32665418]
  • Mohamed E Shaker, Ahmed A Shaaban, Mohamed M El-Shafey, Mohamed E El-Mesery. The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies. Toxicology and applied pharmacology. 2020 07; 398(?):115018. doi: 10.1016/j.taap.2020.115018. [PMID: 32333917]
  • Kareem M Saad, Mohamed E Shaker, Ahmed A Shaaban, Rehab S Abdelrahman, Eman Said. The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity. International immunopharmacology. 2020 Apr; 81(?):106292. doi: 10.1016/j.intimp.2020.106292. [PMID: 32062076]
  • Chunling Zhou, Jinmiao Tian, Peng Lin, Tianzhu Liu, Aiping He, Lina Fang, Lingling Sun. Quantitation of capmatinib, a mesenchymal-epithelial transition factor inhibitor by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study. Bioanalysis. 2020 Mar; 12(5):285-293. doi: 10.4155/bio-2020-0011. [PMID: 32186402]
  • Xiaoguang Fan, Guanghu Yang, Wenjuan Cui, Qin Liu, Zhaolong Zhang, Zhikun Zhang. Development and full validation of an LC-MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats. Biomedical chromatography : BMC. 2020 Mar; 34(3):e4768. doi: 10.1002/bmc.4768. [PMID: 31821576]
  • Taito Esaki, Fumihiko Hirai, Akitaka Makiyama, Takashi Seto, Hideaki Bando, Yoichi Naito, Kiyotaka Yoh, Kae Ishihara, Tomoyuki Kakizume, Kazuto Natsume, Andrea Myers, Toshihiko Doi. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors. Cancer science. 2019 Apr; 110(4):1340-1351. doi: 10.1111/cas.13956. [PMID: 30724423]
  • Mohamed E Shaker, Sylvia A Ashamallah, Mohamed El-Mesery. The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice. Toxicology letters. 2016 Nov; 261(?):13-25. doi: 10.1016/j.toxlet.2016.08.015. [PMID: 27553677]